Target groups/end users


This Action will be important for patient healthcare by improving the understanding of aldosterone/MR actions in various diseases and proposing novel indications for MR antagonists as previously demonstrated for heart failure or ocular disease. This will improve treatment, personalized medicine, quality of life and help reduce healthcare costs.

Healthcare providers

This action will provide new diagnostic tools and identify additional or novel treatment tools or strategies for common diseases in the cardiovascular/renal/metabolic field, leading to scientific, societal and economic benefits.

Research communities

This Action will support networking and collaborations among researchers in the field, and importantly also in allied fields, thus catalysing innovation in this research domain. The results of this COST Action will make important contributions to hormone and steroid receptor research, to the cardiovascular/renal/metabolic field and has high potential to foster ground-breaking scientific breakthroughs. The panel will develop new tools such as specific monoclonal antibodies and animal models which will also find use in allied fields of physiology and pathophysiology of steroid hormone actions and associated disease states.

Biotechnology and pharmaceutical industry

The COST partners working more closely together will foster a more detailed molecular dissection of the signalling pathways of aldosterone synthesis and aldosterone/MR action in various physiological and pathological contexts, leading to the generation of novel diagnostic tool and new therapeutic targets. Generation of antibodies, novel cell lines with MR mutants or new sets of genetic probes to assess MR activation/inhibition will provide an important toolset to validate novel MR antagonists with more selective or tissue-specific action.